JESSICA CABRERA: Open Payments
NPI 1265641435 · HARLINGEN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,969 in 69 payments from 11 companies in 2025. Trend: 2023 $1,780 · 2024 $1,700 · 2025 $2,969
Food & beverage: $2,855Education: $114
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 11 | $568 |
| Teva Pharmaceuticals USA, Inc. | 12 | $524 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $411 |
| ABBVIE INC. | 5 | $299 |
| Alkermes, Inc. | 4 | $284 |
| Vanda Pharmaceuticals Inc. | 5 | $279 |
| Neurocrine BioSciences, Inc. | 4 | $202 |
| E.R. Squibb & Sons, L.L.C. | 10 | $191 |
| Axsome Therapeutics, Inc. | 6 | $162 |
| Lundbeck LLC | 1 | $25 |
Products named: REXULTI, CAPLYTA, UZEDY, VRAYLAR, FANAPT, LYBALVI, INGREZZA, COBENFY.
Industry payments across TX — which companies pay providers there.
